spliceosome

spliceosome. The spliceosome is a massive, dynamic ribonucleoprotein complex that catalyzes the removal of non-coding intron sequences from precursor messenger RNA (pre-mRNA) and ligates the flanking exons. This process, known as RNA splicing, is a critical step in eukaryotic gene expression, essential for producing mature mRNA that can be translated into functional proteins. Composed of five small nuclear ribonucleoprotein particles (snRNPs) and numerous auxiliary proteins, the spliceosome assembles anew on each intron through a highly orchestrated series of ATP-dependent rearrangements.

Structure and composition

The core components of the major spliceosome are the five uridine-rich small nuclear ribonucleoprotein particles: U1, U2, U4, U5, and U6. Each snRNP consists of a specific small nuclear RNA (snRNA) molecule, a set of common Sm proteins, and several unique particle-specific proteins. For instance, the U1 snRNP recognizes the 5' splice site, while the U2 snRNP binds the branch point adenosine within the intron. The complex also incorporates a large number of non-snRNP proteins, such as those from the SR protein family and the heterogeneous nuclear ribonucleoprotein (hnRNP) family, which facilitate assembly and regulate splicing fidelity. Structural studies, including those using cryo-electron microscopy, have revealed the spliceosome's intricate architecture, showing how components like the NineTeen Complex (NTC) and the Prp19 complex stabilize the active site.

Function in pre-mRNA splicing

The primary function of the spliceosome is to execute the two transesterification reactions of pre-mRNA splicing. First, the 2' hydroxyl group of the branch point adenosine, typically within a conserved sequence recognized by the SF1 and U2AF proteins, attacks the 5' splice site, forming a lariat intermediate. Second, the newly freed 3' hydroxyl of the upstream exon attacks the 3' splice site, resulting in exon ligation and intron release. This precise excision is guided by complementary base-pairing interactions between the snRNAs and conserved pre-mRNA sequences at the splice sites, the branch point, and the polypyrimidine tract. The process ensures the accurate removal of introns, which can be exceptionally long, as seen in genes like Dystrophin, and is crucial for generating proteomic diversity through alternative splicing.

Assembly and catalytic cycle

Spliceosome assembly follows a stepwise pathway, beginning with the commitment complex (E complex) formed by the recognition of the 5' splice site by U1 snRNP and the 3' region by U2AF and SF1. This is followed by the pre-spliceosome (A complex), where U2 snRNP stably engages the branch point, a step requiring ATP hydrolysis. The subsequent recruitment of the U4/U6.U5 tri-snRNP forms the pre-catalytic B complex. Major structural rearrangements, catalyzed by RNA helicases like Brr2 and Prp2, lead to the displacement of U1 snRNP and U4 snRNP, activating the complex. The catalytically active B^act and C complexes then perform the two chemical steps. Finally, the post-catalytic complex is disassembled by helicases such as Prp22 and Prp43, releasing the mRNA and the intron lariat for degradation by the Debranching enzyme and exosome.

Evolution and conservation

The spliceosome is a hallmark of the eukaryotic lineage, with its core machinery highly conserved from yeast to humans. Comparative genomics indicates that the spliceosomal snRNAs and many protein components, including Sm proteins and Prp8, have deep evolutionary roots. The spliceosome is believed to have evolved from Group II self-splicing introns, with the catalytic RNA core potentially derived from the intron RNA itself and proteins being added over time. This evolutionary relationship is supported by similar reaction mechanisms and the conservation of RNA structures. While the major (U2-type) spliceosome is ubiquitous, a minor (U12-type) spliceosome, utilizing distinct snRNPs like U11 snRNP and U12 snRNP, processes a rare class of introns and is found in various eukaryotic lineages, suggesting an ancient divergence.

Clinical significance

Mutations in spliceosomal components or in the cis-regulatory splicing signals of pre-mRNAs are a major cause of human disease. For example, mutations in SF3B1, a core component of the U2 snRNP, are frequently observed in myelodysplastic syndromes and chronic lymphocytic leukemia. Aberrant splicing due to mutations in the Survival of motor neuron 1 (SMN1) gene leads to spinal muscular atrophy. Furthermore, targeting the spliceosome has emerged as a therapeutic strategy; drugs like Plicamycin and Spliceostatin A modulate splicing and are investigated for cancers. The recognition of widespread alternative splicing aberrations in conditions like Huntington's disease and cystic fibrosis underscores the complex's central role in health and disease.

Category:Molecular biology Category:RNA Category:Gene expression